Michael A. Finan, M.D.
Director, USA Mitchell Cancer Institute
Abraham A. Mitchell Chair
Senior Staff Physician, MCI Division of Gynecologic Oncology
Professor of Interdisciplinary Clinical Oncology
Prior to his appointment as director in 2015, Michael A. Finan, M.D., served as interim director of MCI (2014-2015), chief of the MCI Division of Gynecologic Oncology (2005-2015) and associate director for Clinical Affairs (2014-2015). He specializes in a variety of gynecologic cancers, including cervical, vaginal, endometrial, vulvar, fallopian tube and ovarian cancer as well as gestational trophoblastic neoplasia. Dr. Finan was the first gynecologist in Mobile to perform robotic surgery with the DaVinci Robotic Surgery System and has been listed among Top Cancer Doctors by Newsweek and Top Doctors by U.S. News and World Report. He is an associate member of the NCI Early Detection Research Network working group and maintains an active collaboration with MCI physicians and scientists in the area of gynecologic cancer research. Dr. Finan is a co-founder of the GO Run in Mobile, a run held each September to raise funds for gynecologic oncology research at MCI. Intellectual property emanating from his research has been licensed to Swift Biotechnology to develop a commercial method for the collection and clinical testing processes related to the early detection of endometrial and ovarian cancers using protein biomarkers. He is a co-inventor on six patents related to ovarian cancer screening technology.
Rodney P. Rocconi, M.D., joined MCI as a physician-scientist in the Gynecologic Oncology Service in 2007 and was named associate director for Clinical Research in 2011. Under his leadership, enrollment in clinical trials has increased dramatically. He is a board certified gynecologic oncologist with an active and productive research career credited with more than 100 presentations at national and international meetings and more than 80 publications. His research interests focus on understanding the molecular mechanisms involved in ovarian cancer stem cells, specifically chemoresistance, as well as genetic contributions of racial health-care disparities in gynecologic malignancies. His research program is supported by multiple NCI/NIH and foundation grants, and he has served as principal investigator on a R01 grant for a site-specific proteomics-based screening study in ovarian cancer. This work led to an associate membership with the NCI Early Detection Research Network working group and resulted in patents on intellectual property. Dr. Rocconi has been recognized for his work as a recipient of the Gynecologic Cancer Foundation Ovarian Cancer Research Award and the Gynecologic Oncology Young Investigator Research Award.
Margaret Sullivan, M.S.
Associate Director, Cancer Control and Prevention
Margaret Sullivan received her undergraduate degree from Stanford University in Human Biology with a concentration in Health Care Management, and a Master of Science degree in Health Policy and Management from the Harvard T.H. Chan School of Public Health. Prior to joining MCI, she worked as a senior consultant for FLR Health Resources, a health-care consulting firm based in Atlanta. She has served in numerous capacities for the University of South Alabama, including strategic planning for the health system and the development of a Medicaid 1115 Demonstration Waiver for the University's HMO. She was instrumental in the conception of a cancer institute at USA, spearheading the feasibility study in 2000, serving as project manager, recruiting faculty, selecting the architectural firm, overseeing space planning and developing outreach programs. She was appointed deputy director for Business Development and Outreach in 2012, when her responsibilities included overseeing physician, employer and community outreach efforts, overseeing marketing and public relations, and developing collaborations in cancer control and prevention. She served as principal investigator on a colorectal education grant funded through the Alabama Department of Public Health and Centers for Disease Control and Prevention from 2012 to 2014. In her current capacity, she is charged with setting strategic direction for MCI cancer control and population health initiatives, recruiting faculty and growing the peer-reviewed cancer control extramural funding base.
© 2018 USA Health